KBC Group
ICPT

KBC Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

KBC Group’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-897
Closed -$147K – 1341
2016
Q3 		$147K Buy
897
+779
+660% +$123K ﹤0.01% 1190
2016
Q2 		$17K Sell
118
-147
-55% -$21.4K ﹤0.01% 1259
2016
Q1 		$34K Hold
265
– – ﹤0.01% 1211
2015
Q4 		$40K Hold
265
– – ﹤0.01% 1206
2015
Q3 		$44K Hold
265
– – ﹤0.01% 1246
2015
Q2 		$64K Sell
265
-5,576
-95% -$1.48M ﹤0.01% 1298
2015
Q1 		$1.65M Sell
5,841
-9,378
-62% -$2.03M 0.02% 601
2014
Q4 		$2.37M Buy
15,219
+11,866
+354% +$2.19M 0.03% 542
2014
Q3 		$794K Sell
3,353
-19,540
-85% -$4.98M 0.03% 602
2014
Q2 		$5.42M Buy
+22,893
New +$6.03M 0.06% 372

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

KBC Group's ICPT Position: Q4 2016 in Review

KBC Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2016, closing a stake of 897 shares — an estimated $147K sold.

KBC Group first reported a position in ICPT in Q2 2014 and held it in 10 quarters. The position peaked at $5.42M in Q2 2014. 159 funds tracked by Wall St. Rank hold ICPT as of Q4 2016.

  • KBC Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • KBC Group sold 897 Intercept Pharmaceuticals, Inc. shares in Q4 2016, an estimated $147K.
  • KBC Group first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 10 quarters.
  • KBC Group's Intercept Pharmaceuticals, Inc. position peaked at $5.42M in Q2 2014.
  • 159 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2016.

Based on KBC Group's 13F filing for Q4 2016, filed 16 Feb 2017.